Breakdown | |||||
TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
1.74M | 0.00 | 700.00K | 1.42M | 0.00 | 0.00 | Gross Profit |
604.00K | -1.21M | -11.24M | -550.00K | -665.00K | -666.00K | EBIT |
-48.53M | -43.57M | -58.06M | -63.01M | -49.97M | -47.95M | EBITDA |
-47.33M | -42.37M | -56.70M | -61.87M | -48.87M | -46.79M | Net Income Common Stockholders |
-46.13M | -42.21M | -58.95M | -63.16M | -49.74M | -45.99M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
59.58M | 44.37M | 61.14M | 28.61M | 20.48M | 25.40M | Total Assets |
70.64M | 59.15M | 77.88M | 54.25M | 41.29M | 41.91M | Total Debt |
0.00 | 9.14M | 75.96M | 11.25M | 11.36M | 6.72M | Net Debt |
-51.10M | -35.22M | 14.82M | -17.36M | -1.11M | -180.00K | Total Liabilities |
4.31M | 14.79M | 80.13M | 18.56M | 18.40M | 11.18M | Stockholders Equity |
66.33M | 44.36M | -2.25M | 35.69M | 22.89M | 30.74M |
Cash Flow | Free Cash Flow | ||||
-34.09M | -33.16M | -47.41M | -54.53M | -35.81M | -34.79M | Operating Cash Flow |
-33.98M | -33.04M | -47.01M | -54.10M | -35.37M | -34.19M | Investing Cash Flow |
-115.00K | -121.00K | -401.00K | 7.56M | 10.04M | -10.10M | Financing Cash Flow |
62.74M | 16.39M | 79.94M | 62.69M | 30.89M | 82.00K |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
61 Neutral | $27.46B | 49.32 | 27.63% | ― | 11.34% | 4.24% | |
60 Neutral | $276.83M | ― | -38.45% | ― | 15.29% | 45.45% | |
57 Neutral | $1.25B | ― | -6.14% | ― | -20.89% | 83.44% | |
49 Neutral | $6.84B | 0.05 | -53.14% | 2.48% | 24.49% | -3.26% | |
48 Neutral | $1.05B | ― | -70.28% | ― | ― | 12.66% | |
46 Neutral | $2.52B | ― | -50.74% | ― | -7.03% | -20233.78% | |
35 Underperform | $3.70M | ― | 366.81% | ― | -30.19% | 97.74% |
On January 14, 2025, Pulse Biosciences released an updated investor presentation on their website highlighting recent advancements in their cardiac treatment product line. This update is intended to inform investors and analysts about the progress in their product development programs, potentially impacting company operations and stakeholder decisions.
Pulse Biosciences announced the appointment of Paul A. LaViolette as Chief Executive Officer and President, effective January 9, 2025. Mr. LaViolette, who has extensive experience in the healthcare and medical technology sectors, will also act as the principal executive and financial officer. This appointment comes with an at-will Employment Agreement, including stock options contingent on performance milestones. The announcement signals a strategic move to leverage Mr. LaViolette’s expertise to enhance the company’s positioning in the medical technology industry, particularly in its innovative nano-PFA technology development and market expansion efforts.
Pulse Biosciences, Inc. announced the resignation of CEO Burke T. Barrett, with no disputes over company policies or practices. The company continues to advance its nano-PFA devices as planned. Barrett receives salary, severance, stock options, and health benefits per his separation agreement. Kevin P. Danahy and Darrin R. Uecker temporarily assume executive roles until a new CEO is appointed.
Robert W. Duggan, the controlling stockholder and Co-Chairman of Pulse Biosciences, Inc., is considering buying up to 500,000 shares of the company’s common stock by December 2024. This move, approved under the company’s Insider Trading Policy, could potentially influence the market perception and value of Pulse Biosciences’ stock.